ALK Positive Malignancies research hub

Roll-over Study to Allow Access to Certinib (LDK378) for Patients Who Are on Ceritinib Treatment in a Novartis-sponsored Study

This study offers ongoing access to ceritinib for patients already benefiting from it in another Novartis study. It's for people with ALK-positive cancers who, along with their doctor, believe continued treatment is helping them.